GlassScriptPhysician profile
Catherine Y Taras
NPI 1649236464
$1,288.96
in general payments reported to CMS, 2019-2025
22 companies · $35.80 in 2025
The $35.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $67.14 · 2021: $114 · 2022: $206 · 2023: $524 · 2025: $35.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $220.11 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $214.74 | 2023 | Qulipta, Ubrelvy, Vraylar |
| Lilly USA, LLC | $143.53 | 2022-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $98.99 | 2019-2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $77.71 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.48 | 2022 | |
| Astellas Pharma US INC | $61.24 | 2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $49.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $43.67 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.70 | 2019 | |
| Almatica Pharma LLC | $39.03 | 2021-2022 | |
| Pfizer INC. | $31.86 | 2023 | |
| Amarin Pharma, INC. | $31.70 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $27.81 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.51 | 2023 | Jynarque |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.08 | 2022 | |
| Dynavax Technologies Corporation | $16.75 | 2023 | Heplisav-B |
| Horizon Therapeutics Plc | $13.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.63 | 2019 | |
| Bausch Health US, LLC | $11.99 | 2019 | |
| Allergan, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Taras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.